Trial intelligence / Profile preview

IncobotulinumtoxinA individualized dosing for severe spasticity

2022-004127-40Phase 3Active

Sponsor: Dra. Nuria Gutierrez DubÃ³n
Start: Jan 2023
Modality: Recombinant Proteins and Enzymes
Countries: 1

Overview

Phase 3, single-arm trial of botulinum toxin type A in Muscle spasm, sponsored by Dra. Nuria Gutierrez DubÃ³n. Primary endpoint: Ashworth scale change at 6 weeks. Started Jan 2023; status: active.

Drugs

botulinum toxin type A

Conditions

Muscle spasm

Beyond the preview

Go deeper on 2022-004127-40.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2022-004127-40.